Management of the Hormone Sensitivity of Prostate Cancer: Where Are We Now?

European Urology

Volumn 54, Issue 2, 2008, Pages 247-250

  Alcaraz, Antonio ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN THERAPY; ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HOT FLUSH; HUMAN; INSULIN RESISTANCE; LIBIDO DISORDER; LIFE EXPECTANCY; METASTASIS; MUSCLE ATROPHY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 45849139322     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.02.042     Document Type: Editorial

References (13)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer I. The effect of castration, estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Byar D.P., and Corle D.K. Hormone therapy for prostate cancer: results of the Veterans' Administration Cooperative Urological Research Group studies. J Natl Cancer Inst Monogr 7 (1988) 165-170
3. Schally A.V., Arimura A., Baba Y., et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 43 (1971) 393-399
4. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311 (1984) 1281-1286
5. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
6. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
7. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 25 (2007) 1596-1605
8. D'Amico A.V., Kantoff P., Loffredo M., et al. Predictors of mortality after prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 65 (2006) 656-660
9. D'Amico A.V., Moul J.W., Carroll P.R., et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 96 (2004) 509-515
10. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876
11. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
12. Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. 2007 ASCO Annual Meeting Proceedings.
13. Irani J., Celhay O., Hubert J., et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 54 (2008) 382-391